公司概述
Scienture Holdings, Inc. operates within the healthcare sector, specifically functioning as a pharmaceutical retailer that focuses on the development and commercialization of products for treating central nervous system and cardiovascular diseases in the United States. The company's operational structure is segmented into Integra and Scienture, with the Integra segment engaged in specific business activities that contribute to its overall portfolio. In terms of scale, the company maintains a market capitalization of $14.22M and employs approximately 4 individuals to execute its strategic initiatives. The annual revenue generated over the trailing twelve months stands at $431,609, which, when viewed alongside the market cap, indicates a highly capitalized entity relative to its current revenue stream. This discrepancy suggests that the market valuation is not primarily driven by current cash flow or profitability metrics but rather by potential future developments in its pharmaceutical pipeline or strategic positioning within the specialized therapeutic areas it targets.
财务健康
The company reported a revenue of $431,609 for the trailing twelve months, yet it simultaneously recorded a net income of $-41,512,264 and an EBITDA of $-15,788,946, revealing a significant structural gap between top-line generation and bottom-line profitability. The substantial disparity between the positive revenue figure and the massive negative net income implies that operating expenses and other costs far exceed the revenue generated, resulting in a net loss that outweighs the total income by orders of magnitude. Free cash flow for the period was reported at $-362,075, indicating that the company is currently consuming cash reserves to fund its operations and development efforts rather than generating surplus liquidity. Regarding profitability margins, the gross margin stands at 76.8%, which suggests high efficiency in the cost of goods sold relative to revenue, while the operating margin is reported at an anomalous 1869.8% and the profit margin is 0.0%, highlighting extreme volatility or specific accounting adjustments in its cost structure. On the balance sheet, the company holds $6.66M in cash against $24,137 in debt, resulting in a debt-to-equity ratio of 0.03, which characterizes a highly conservative leverage profile with minimal financial obligations relative to equity. The current ratio is 2.89, signifying that the company possesses more than twice the liquid assets required to cover its short-term liabilities, providing a strong buffer against immediate liquidity pressures. Return on Equity is recorded at -55.6% and Return on Assets at -10.7%, metrics that collectively reveal that management has not yet achieved positive returns on the capital deployed or assets held, reflecting the early-stage or loss-making nature of the business model.
估值评估
Valuation metrics for Scienture Holdings, Inc. present a complex picture, with the trailing P/E ratio listed as N/A due to the lack of positive earnings, while the forward P/E is calculated at -1.67, implying that expected future earnings are anticipated to be negative or that the market is pricing in a turnaround scenario. The price-to-book ratio is 0.20, indicating that the stock trades at a significant discount to its book value, which often suggests the market perceives the assets on the balance sheet as potentially overvalued or that the company faces substantial intangible liabilities not fully captured in the book value. The price-to-sales ratio is 32.95, a figure that is exceptionally high relative to the small revenue base, suggesting that investors are willing to pay a premium for potential future growth rather than current cash generation. Additionally, the EV/EBITDA ratio stands at -0.48, further reinforcing that traditional enterprise value multiples are distorted by the company's negative earnings and cash flow position. Price momentum data shows a 52-week high of $2.60 and a 52-week low of $0.24; without a specific current price provided in the facts, the valuation range indicates a wide band of volatility where the stock could theoretically trade anywhere within this spread, reflecting high uncertainty regarding its future performance. The beta value is listed as N/A, meaning there is insufficient data to quantify the stock's volatility relative to the broader market, though the wide gap between the high and low suggests inherent price instability.
Growth & Income
Growth metrics for the company are currently unavailable, with revenue growth year-over-year and earnings growth year-over-year both listed as N/A, preventing a direct comparison of earnings expansion relative to top-line growth. Consequently, it is impossible to determine from the provided data whether earnings are growing faster or slower than revenue, as the necessary historical data points to calculate these rates do not exist in the current reporting period. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the firm is retaining all of its limited earnings to reinvest into research, development, or operational expansion rather than distributing cash to shareholders. This reinvestment strategy is typical for companies in the pharmaceutical development space that prioritize long-term asset creation and pipeline development over immediate income distribution. Overall, the growth and income profile is characterized by a total lack of dividend income and undefined growth rates, signaling a capital-intensive phase where financial returns to shareholders are deferred in favor of corporate development activities.